A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer
A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer
Active, not recruiting · NCT04506554 · Registry updated 2026-09-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer | Muscle-Invasive Bladder Carcinoma | Active, not recruiting | Phase 2 | 2026-09-21 | NCT04506554 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fox Chase Cancer Center | 58 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fox Chase Cancer Center - Philadelphia | Philadelphia | United States | 10 |
| Thomas Jefferson University Hospital | Philadelphia | United States | 271 |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill | United States | 243 |
| UT Southwestern Medical Center | Dallas | United States | 210 |